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introduction
Glioblastoma is the most common and most malignant form
of primary brain tumors in adults. It frequently develops
de novo but may also evolve over years from a lower grade
astrocytoma [1]. Recent combined modality treatments have
led to some improvement in survival. However, most patients
will still succumb to their disease (median survival to
15 months and 2-year survival rates of 26%) [2, 3].
Correlative molecular studies and animal models have
identified numerous molecular alterations and biological
processes involved in initiation and progression of glioma.
However, the underlying molecular mechanisms and pathways
involved are complex and remain poorly understood. The
accumulation of multiple aberrations in regulatory processes
enables tumor cells to bypass the effects of many of the available
therapies. Molecular alterations underlying such mechanisms
comprise aberrations on the genetic level, e.g. point mutations
in key genes or respective amplifications and deletions [1],
or are a consequence of epigenetic modifications. The latter
include aberrant methylation of CpG islands in the regulatory
sequence of genes, as well as changes in chromatin structure
mediated by mechanisms such as histone acetylation.
Hypermethylation of CpG islands in the promoter of genes leads
to loss of expression (inactivation), while loss of methylation in
normally silenced genes may cause inappropriate expression
(e.g. IGF2 gene), both with tumor promoting effects [4, 5].
Individual molecular tumor profiles are heterogeneous implying
that different therapeutic approaches will be necessary for
successful personalized treatments.
A first step towards the design of novel therapies is the
identification and better understanding of relevant molecular
mechanisms driving the aggressive biological behavior that
subsequently may be targeted in respective treatment
approaches. Hanahan and Weinberg [6] categorized the
principle biological requirements for tumor formation as
follows: (i) self sufficiency in growth signals, (ii) insensitivity to
anti-growth signals, (iii) limitless replicative potential, (iv)
sustained angiogenesis, (v) evasion from apoptosis and (vi)
tumor infiltration and metastasis. The molecular aberrations
conferring these properties in tumors are diverse, although they
show some characteristic tumor type and malignancy grade
dependent patterns. Molecular tumor profiles may become
helpful tools to device therapeutic strategies aiming for
individually tailored treatments.
molecular profiles indicate biological
features differentiating glioma
subtype and tumor grade
Glioma subtypes exhibit distinct molecular profiles (Figure 1)
[1, 7–9]. A hallmark of primary glioblastoma is the
amplification of epidermal growth factor receptor gene (EGFR)
that is often associated with deletion of the CDKN2Ap16/Arf gene
encoding two tumor suppressors, p16 an inhibitor of CDK4 and
p14ARF a negative regulator of MDM2. These two aberrations
are mutually exclusive with mutations in the TP53 tumor
suppressor gene that represent a hallmark in the evolution of
secondary glioblastoma [10, 11]. Primary and secondary
glioblastoma, although histologically undistinguishable, are
distinct disease entities that occur in different age groups.
Childhood glioblastoma, frequently situated in the brain stem,
form a third pathogenetically distinct group from their adult
counterparts [12, 13].
Oligodendroglioma, characterized by combined loss of
heterozygosity on chromosomes 1p and 19q, rarely exhibit
mutations in the TP53 gene or amplification of EGFR, but in the
majority have an epigentically inactivated O6-methylguanine-
DNA methyltransferase (MGMT) repair gene that may explain
their particular sensitivity to alkylating agent therapy.
The distinct genomic aberrations translate into characteristic
differences of global gene expression profiles of glioma subtypes
(Figure 2) [14, 15]. Interestingly, differential gene expression
profiles distinguishing primary glioblastoma from low grade
astrocytoma, and surprisingly also from secondary glioblastoma
identified a group of correlated genes related to angiogenesis
and hypoxia. This may guide the use of anti-angiogenic
treatment strategies [14].
Most glioblastoma (80%) exhibit inactivation of the p14ARF/
TP53/MDM2 pathway concurrent with abnormalities in G1-
transition control. The latter is a consequence of aberration of
either RB1, CDK4, CDKN2A or CDKN2Bp15 genes involved in
the same pathway of cell cycle control [16]. Associations of
genetic aberrations such as EGFR amplification and concurrent
deletion of the CDKN2Ap16/Arf gene locus [7] are suggestive of
a cooperative effect. This hypothesis is further supported by in
vivo and in vitro models, and may have relevant consequences
for resistance to respective targeted treatments [17, 18].
As molecular data on glioma accumulates, attempts are made
to identify predictors of prognosis and response to therapy.
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Recent comprehensive molecular profiling efforts provided
evidence for the existence of molecular subtypes of glioblastoma
that may differ in their clinical behavior [19–28]. Several
prognostic factors emerged from these and other retrospective
studies. However, the insights gained will require validation in
independent data sets and prospective clinical trials to
determine their predictive value for response to specific
therapeutic interventions.
prognostic molecular markers improve
diagnostic precision
Tumor histology and malignancy grade guide treatment
decisions while taking into account clinical parameters such as
age, performance status and extent of tumor resection, are all
important prognostic factors. Identification of molecular
prognostic markers will be crucial for the design of future trials.
However, many markers may just reflect a different natural
history and not necessarily contribute to decisions for individual
patient management. Nevertheless, molecular markers may
greatly improve diagnostic precision and characterize tumor
entities with distinct biological behavior.
The best example is the identification of oligodendroglioma
with loss of heterozygosity on chromosomes 1p and 19q (LOH
1p/19q). This tumor type is associated with high response rates
to chemotherapy and a prolonged survival [8, 29].
Recently, the outcome of anaplastic oligoastrocytoma and
oligodendroglioma treated within two independent randomized
trials with a similar design was reported by the Radiotherapy
Oncology Group (RTOG) and the European Organization of
Research and Treatment of Cancer (EORTC) [30, 31]. In these
trials PCV-chemotherapy was administered either before
(RTOG) or after radiotherapy (EORTC), respectively.
Combined losses on chromosomes 1p and 19q represented
a favorable prognostic marker and characterized a distinct
glioma entity independent of whether initial treatment included
PCV chemotherapy or not. Patients with oligodendroglioma
with LOH 1p/19q had a much better outcome than patients
without LOH 1p/19q. Chemotherapy prolonged progression-
free survival in all patients but failed to improve overall survival,
even the subset of patients considered the most sensitive to
Figure 1. Distinct pathogenetic pathways characterize malignant progression of gliomas. A hallmark of primary glioblastoma is the amplification of the EGFR
that is often associated with deletion of the CDKN2Ap16/Arf gene encoding two tumor suppressors. These aberrations are mutually exclusive with mutations in
the TP53 tumor suppressor gene that represent a hallmark in the evolution of secondary glioblastoma. Primary and secondary glioblastoma occur in different
age groups. Combined loss of heterozygoity on chromosomes 1p and 19q are characteristic for oligodendroglioma. They rarely exhibit mutations in the
TP53 gene or amplification of the EGFR. Information is compiled from the literature in particular from the [1, 7–9, 62].
Figure 2. Gene expression profiles differentiate glioma subtypes. MDS
(multidimensional scaling) based on overall gene expression (1185 genes)
of 51 astrocytic gliomas. The color code indicates the tumor subtype
according to histological and clinical criteria. LGA, low grade astrocytoma;
ScGBM, secondary glioblastoma; PrGBM, primary glioblastoma.
With permission from [19].
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chemotherapy with LOH 1p/19q. Hence we need to conclude
that LOH 1p/19q is primarily a prognostic factor describing
a distinct pathologic entity. Its determination improves the
accuracy of morphologic diagnosis overcoming subjective
interobserver differences that have severely limited
comparability between institutions and treatments [32].
Consequently, the ongoing European and Canadian trial
(EORTC 22033/26033) for low grade glioma stratifies the
patients for 1p deletions in the tumor.
targeted treatments
As pathogenetic factors are diverse, multiple treatment strategies
are possible. The integration of clinical and molecular
information has provided a list of mechanisms that may be
targeted. Aspects of selected treatment strategies are highlighted
below. Otherwise reference is given to recent comprehensive
reviews of the respective fields.
DNA-repair-driven therapeutics
Epigenetic silencing of the MGMT gene encoding a DNA
repair enzyme was recently found to be of predictive value for
benefit from the alkylating agent temozolomide (TMZ) in
a randomized clinical trial for newly diagnosed glioblastoma
[33]. The trial had shown that the addition of concomitant and
adjuvant (maintenance) TMZ to radiotherapy (RT) improved
the 2-year survival rate from 10% in the RT group to 26% for
TMZ/RT, setting a new standard of care for glioblastoma
patients [3]. Subsequent analysis of the patient’s tumor tissues
revealed that benefit of the addition of TMZ chemotherapy was
basically confined to patients whose tumors had a methylated
MGMT promoter [33]. At 2 years, 46% of the patients treated
with TMZ/RT and whose tumors were MGMT methylated
survived, compared to only 14% for the patients with
unmethylated tumors. High expression of the MGMT repair
enzyme is known to reverse part of the treatment effect of
alkylating agents by rapidly repairing O6-methyl guanine, the
biologically most important lesion for triggering a cytotoxic
response [34, 35]. Since the MGMT protein is a suicide repair
enzyme that gets inactivated when the alkyl group from the
lesion is transferred to the active site of the enzyme, depletion of
the enzyme from the tumor cells may be used as a therapeutic
strategy to improve sensitivity to alkylating agents. One
approach uses a non-cytotoxic substrate of MGMT, such as
O6-BG (O6-benzylguanine) or PaTrin-2 [O(6)-(4-
bromothenyl)guanine] [36] that may deplete cells of the repair
enzyme. Phase I clinical trials have evaluated O6-BG in
association with TMZ or carmustine (BCNU) [37, 38]. An
alternative strategy is to use an intensified, dose-dense TMZ
administration schedule aiming at depleting MGMT by
continued exposure. This approach is currently undergoing
clinical testing within a large randomized international
Intergroup trial (RTOG0525/EORTC26052–22053) [39].
Patients are stratified prior to randomization by their MGMT
methylation status. [For additional information, see http://
www.rtog.org or http://www.eortc.org or contact the study
chairs: Mark Gilbert (mrgilbert@mdanderson.org ) or Roger
Stupp (roger.stupp@chuv.ch).] The cytotoxic property of the
O6-methyl guanine lesion that persists in the DNA in absence
of functional MGMT, depends on an intact mismatch
repair (MMR) system that eventually triggers the signaling
pathways leading to cell death [40, 41]. Thus, best response
is expected in patients whose tumor is deficient for MGMT,
but proficient for MMR. In adult glioblastoma there is no
evidence for lack of MMR, in contrast to pediatric
glioblastoma [13]. However, additional resistance factors
exist, and may include abrogation of apoptosis pathways
and deregulated survival signaling that need to be identified
and subsequently overcome.
Other approaches aim at rescuing or increasing sensitivity to
alkylating agent therapy by inactivating base excision repair
(BER) [42]. Approaches have been to use methoxyamine that
inhibits apurinic/apyrimidinic endonuclease (APE)-mediated
cleavage by binding to AP-sites; while inhibition of Poly(ADP-
ribose)polymerase-1 (PARP) impairs the recruitment of BER
proteins [43]. This approach has been effective in breast cancer
models with either defective BRCA1 or BRCA2 that are both
involved in repair of double strand breaks [44]. In glioblastoma
cell lines or respective xenograft models PARP inhibitors proved
to be particularly effective when MMR was deficient [45, 46].
The redundancy in the targeted pathway, in this case repair, has
to be overcome in order to achieve a successful treatment
response. Hence, targeting repair processes might be
a promising strategy for improving efficacy of alkylating
agent chemotherapy.
small molecule inhibitors
Over the last years small molecule drugs have been developed
specifically inhibiting aberrantly activated signaling pathways.
These pathways may not only be activated in the tumor cells
themselves, but also in the tumor stroma and tumor-associated
endothelial cells [47]. Thus targeting of respective pathways
operative in different compartments, or inhibitors of multiple
tyrosine kinases, such as PTK-787, may have synergistic effects
and thereby enhance treatment efficacy. Evaluation of these
small molecule drugs, including peptides, polypeptides and
antibodies specifically targeting signaling pathways aberrantly
activated in gliomas will be central to future clinical trials
(recently reviewed in [48]) (Figure 3). Based on molecular
profiles of glioblastoma, the EGFR- and PI3K-pathway and their
downstream partners represent particularly attractive targets
[49, 50]. Promising are also strategies that particularly aim at
angiogenesis [47] such as inhibitors of vascular endothelial
growth factor (VEGF), vascular endothelial growth factor
receptor (VEGFR), or inhibitors of integrins [51]. However,
based on modest responses in trials with single agents, and
encouraging synergistic effects in preclinical studies,
combination treatments are warranted, combining cytotoxic
agents plus one or several targeted drugs (or molecules targeting
multiple pathways) [52, 53]. Many new targeted drugs, or
combinations thereof, are currently tested or have been tested in
phase I or II trials [53, 54]. One limitation in the clinic is the
frequent interaction with the commonly used enzyme-inducing
anti-epileptic drugs.
Since these strategies aim (mainly) at specific molecular
targets it is mandatory to establish molecular profiles of the
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tumors for evaluation of correlations with treatment response.
Since the EGFR represents a particularly attractive target it has
been extensively evaluated in malignant glioma. Retrospective
correlative studies suggested that response to EGFR tyrosine
kinase inhibitors did not depend solely on the presence of the
target, an activated EGFR [54]. Mellinghof et al. [55] proposed
that co-expression of EGFRvIII mutant and PTEN in the tumor
were crucial for response to EGFR inhibitors, while in a study by
Haas Kogan et al. [56] none of the responders expressed
EGFRvIII, but the response was associated with EGFR
amplification and expression, and low levels of PKB/Akt
phosphorylation. Of note, most of these molecular studies were
performed on tumor tissue obtained at the initial diagnosis and
may not reflect the molecular pattern at recurrence after
multiple prior treatment. Molecular analysis of few tumor tissue
samples, available after resection performed during and after
prior therapy with the EGFR inhibitors (erlotinib or gefitinib),
seemed to suggest inefficient inhibition of EGFR
phosphorylation [57]. Thus, the molecular signature relevant
for response to this treatment remains to be elucidated and will
need more in-depth molecular analysis to elucidate the
molecular mechanisms responsible for these unexpected,
additional treatment resistances.
It follows that prospective trials for targeted treatments need
to be designed with an integrated translational research
component allowing for future molecular selection of patients
potentially benefiting from a certain agent or treatment regimen
and identifying the relevant pathways that may need to be
targeted in addition, in order to improve antitumor activity.
Thus, common to all ongoing or planned trials is the absolute
necessity of availability of tumor material for molecular
profiling (paraffin-embedded or ideally fresh-frozen) in order to
establish molecular criteria for the choice of individually
tailored treatment approaches in the future.
outlook: gene signature guide drug
choice
Novel approaches have recently been described identifying gene
expression signatures indicative of oncogenic pathways that
may be specifically targeted for therapy [58, 59]. Using this
Figure 3. Signaling pathways and their inhibitors. Simplified diagram for signaling pathways operative in glioma or in tumor epithelial cells and respective
inhibitors thereof (see also Table 1). The red trait signifies site of specific inhibition. EGF, epidermal growth factor; EGFR, epidermal growth factor receptor;
IGF, insulin-like growth factor; IGFR, insulin-like growth factor receptor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor
receptor; VEGF, vascular endothelial growth factor; VEGFR1 & 2, vascular endothelial growth factor receptor 1 and 2; PI3K, phosphatidylinositol 3-kinase;
PTEN, phosphatase and tensin homolog; PDK1, phosphatidylinositol-dependent kinase; AKT, v-akt murine thymoma viral oncogene homolog; mTOR,
mammalian target of rapamycin; 4EBP, eukaryotic initiation factor 4E (EIF4E)-binding protein; p70S6K, ribosomal protein, S6 kinase 70kD; PP2A, protein
phosphatase 2A; GRB2, growth factor receptor-bound protein 2; SOS, Ras; Raf; MEK, mitogen-activated ERK kinase; and ERK, extracellular-regulated
kinase; TKI, tyrosine kinase inhibitor; AB, specific monoclonal antibodies; FTI, Farnesyltransferase inhibitors.
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concept Solit et al. identified B-raf mutations as predictive for
sensitivity to MEK-inhibition in tumor xenograft models, while
mutations in ras that are further upstream and signals in
addition to other growth promoting pathways led only to
partial response. Thus, gene expression profiles may not only
identify activated oncogenic pathways but also indicate the
presence of redundant pathways that could be responsible for
unexpected resistance to treatment with small molecule drugs,
despite confirmed presence of the activated target. In the future
it might become feasible to deduce, from the tumor derived
gene expression profile of a patient, which oncogenic pathways
are activated and to devise a respective rational combination
treatment. This would conclude the current ‘one fits all’
treatment strategies based on subjective categorization of
morphologic tumor features and some patient characteristics.
Further advances may come from new mouse glioma models
that recapitulate aberrant molecular pathways relevant in
human glioma, or xenograft models of human primary tumors
that may prove to be very useful for testing new small molecule
drugs preclinically [60, 61].
At present, the test for the MGMT-methylation status
represents the only predictive factor for benefit from
treatment that has been evaluated in a clinical trial, but
requires confirmation in ongoing prospective clinical trials.
In the individual management of glioblastoma patients this
information may direct the choice for alkylating agent
chemotherapy, or suggest the addition of alternative
treatment modalities, not depending on MGMT processing.
Hopefully, new predictive factors will become available
within the next years to stratify patients according to their
individual molecular profiles to respective targeted therapies.
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